Trevi Therapeutics’ (TRVI) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI) in a research report released on Wednesday morning,Benzinga reports. The brokerage currently has a $21.00 price objective on the stock.

Other research analysts have also issued reports about the stock. Needham & Company LLC reiterated a “buy” rating and set a $8.00 price objective on shares of Trevi Therapeutics in a report on Friday, November 8th. B. Riley reiterated a “buy” rating and issued a $6.00 price target on shares of Trevi Therapeutics in a report on Monday, October 7th. Leerink Partners started coverage on Trevi Therapeutics in a report on Monday, September 9th. They set an “outperform” rating and a $7.00 price objective for the company. Raymond James began coverage on Trevi Therapeutics in a report on Friday, August 30th. They issued an “outperform” rating and a $9.00 target price on the stock. Finally, Leerink Partnrs upgraded Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $9.13.

Trevi Therapeutics Stock Performance

TRVI stock opened at $2.76 on Wednesday. The company has a 50 day moving average price of $2.99 and a two-hundred day moving average price of $2.91. The stock has a market capitalization of $212.15 million, a P/E ratio of -6.27 and a beta of 0.96. Trevi Therapeutics has a one year low of $1.07 and a one year high of $4.00.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same quarter last year, the firm earned ($0.08) earnings per share. Research analysts forecast that Trevi Therapeutics will post -0.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Trevi Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Logos Global Management LP grew its position in Trevi Therapeutics by 27.3% in the second quarter. Logos Global Management LP now owns 2,800,000 shares of the company’s stock valued at $8,344,000 after acquiring an additional 600,000 shares in the last quarter. Vanguard Group Inc. increased its stake in Trevi Therapeutics by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 2,303,648 shares of the company’s stock worth $7,948,000 after buying an additional 60,249 shares during the period. Ally Bridge Group NY LLC acquired a new position in Trevi Therapeutics in the 2nd quarter worth $4,395,000. Rosalind Advisors Inc. boosted its position in Trevi Therapeutics by 50.3% in the 2nd quarter. Rosalind Advisors Inc. now owns 1,391,577 shares of the company’s stock valued at $4,147,000 after buying an additional 465,561 shares during the last quarter. Finally, MAI Capital Management grew its stake in shares of Trevi Therapeutics by 0.7% during the third quarter. MAI Capital Management now owns 1,327,285 shares of the company’s stock valued at $4,433,000 after acquiring an additional 8,789 shares in the last quarter. 95.76% of the stock is owned by institutional investors and hedge funds.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.